About
CNS treatments
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Team (5)
Clinical Trials (34)
View allTotal Trials
34
As Lead Sponsor
30
As Collaborator
4
Total Enrollment
11,644
By Phase
PHASE3: 20PHASE2: 7PHASE4: 4PHASE1: 1PHASE2/PHASE3: 1
By Status
COMPLETED: 22RECRUITING: 5UNKNOWN: 3TERMINATED: 2ENROLLING_BY_INVITATION: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline34 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06878976Lead Sponsor
Open-Label Safety Study of Solriamfetol in Subjects with Binge Eating Disorder
PHASE3Enrolling by invitation
300 participants
Started: Feb 20, 2025 · Completed: Dec 31, 2026
NCT06736509Lead Sponsor
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
PHASE3Terminated
139 participants
Started: Nov 21, 2024 · Completed: Apr 25, 2025
NCT06568367Lead Sponsor
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
PHASE3Recruiting
520 participants
Started: Aug 1, 2024 · Completed: Dec 31, 2026
NCT06170970Collaborator
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
PHASE2Recruiting
46 participants
Started: Jun 1, 2024 · Completed: Mar 1, 2027
NCT06413433Lead Sponsor
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
PHASE3Recruiting
450 participants
Started: Apr 26, 2024 · Completed: Dec 31, 2025
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...